FDAAA Cornucopia: REMS To Be Used Sparingly; Trial Database On Schedule
Executive Summary
FDA will use its authority to require risk evaluation and mitigation strategies judiciously, according to Chief Medical Officer and CDER Acting Director Janet Woodcock
You may also be interested in...
Clinical Trial Certification Requirements Under FDAAA May Be “Time Bomb”
The section of the FDA Amendments Act that requires companies to post information about their clinical trials contains a "hidden time bomb," according to I. Scott Bass, a partner at the law firm Sidley Austin
FDA’s Drug Safety Office Reorganizing To Accommodate Influx Of PDUFA Staff
FDA's Office of Surveillance and Epidemiology is again undergoing changes as the agency continues to strengthen its drug safety operations. OSE is reorganizing prior to increasing staff by 50 percent to undertake new regulatory authorities
Clinical Trial Certification Requirements Under FDAAA May Be “Time Bomb”
The section of the FDA Amendments Act that requires companies to post information about their clinical trials contains a "hidden time bomb," according to I. Scott Bass, a partner at the law firm Sidley Austin